Amplification of the epidermal growth factor receptor gene in glioblastoma: An analysis of the relationship between genotype and phenotype by CISH method

Neuropathology

Volumn 28, Issue 2, 2008, Pages 116-126

  Miyanaga, Tomomi ^a   Hirato, Junko ^a   Nakazato, Yoichi ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Chromogenic in situ hybridization; Epidermal growth factor receptor; Gene amplification; Glioblastoma; Overexpression

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CELL STRUCTURE; CONTROLLED STUDY; CYTOARCHITECTURE; FEMALE; GANGRENE; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENOTYPE; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; SCHOOL CHILD; TUMOR CELL;

ADOLESCENT; ADULT; AGED; BRAIN NEOPLASMS; CHILD; FEMALE; GENE AMPLIFICATION; GENES, ERBB-1; GENOTYPE; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MIDDLE AGED; NECROSIS; PHENOTYPE;

EID: 41149092491     PISSN: 09196544     EISSN: 14401789     Source Type: Journal    
DOI: 10.1111/j.1440-1789.2007.00853.x     Document Type: Article

References (29)

1. Kleihues P, Cavanee WK, eds. Pathology and Genetics of Tumours of the Nervous System. World Health Organization Classification of Tumours. Lyon : International Agency for Research on Cancer Press, 2000.
2. Wrensch M, Minn Y, Chew T, Bondy M, Berger MS. Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro-oncology 2002 4 : 278 299.
3. Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 2005 64 : 479 489.
4. Halatsch ME, Schmidt U, Behnke-Mursch J, Unterberg A, Wirtz CR. Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours. Cancer Treat Rev 2006 32 : 74 89.
5. Sainsbury JR, Malcolm AJ, Appleton DR, Farndon JR, Harris AL. Presence of epidermal growth factor receptor as an indicator of poor prognosis in patients with breast cancer. J Clin Pathol 1985 38 : 1225 1228.
6. Tateishi M, Ishida T, Mitsudomi T, Kaneko S, Sugimachi K. Immunohistochemical evidence of autocrine growth factors in adenocarcinoma of the human lung. Cancer Res 1990 50 : 7077 7080.
7. Mukaida H, Toi M, Hirai T, Yamashita Y, Toge T. Clinical significance of the expression of epidermal growth factor and its receptor in esophageal cancer. Cancer 1991 68 : 142 148.
8. Ke LD, Adler-Storthz K, Clayman GL, Yung AW, Chen Z. Differential expression of epidermal growth factor receptor in human head and neck cancers. Head Neck 1998 20 : 320 327.
9. Dehais C, Laigle-Donadey F, Marie Y et al. Prognostic stratification of patients with anaplastic gliomas according to genetic profile. Cancer 2006 107 : 1891 1897.
10. Jarvela S, Helin H, Haapasalo J et al. Amplification of the epidermal growth factor receptor in astrocytic tumours by chromogenic in situ hybridization: association with clinicopathological features and patient survival. Neuropathol Appl Neurobiol 2006 32 : 441 450.
11. Smith JS, Tachibana I, Passe SM et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 2001 93 : 1246 1256.
12. Shinojima N, Tada K, Shiraishi S et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 2003 63 : 6962 6970.
13. Quan AL, Barnett GH, Lee SY et al. Epidermal growth factor receptor amplification does not have prognostic significance in patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2005 63 : 695 703.
14. Combs SE, Heeger S, Haselmann R, Edler L, Debus J, Schulz-Ertner D. Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT) - phase I/II trial: study protocol. BMC Cancer 2006 6 : 133.
15. Bilous M, Dowsett M, Hanna W et al. Current perspectives on HER2 testing: a review of national testing guidelines. Mod Pathol 2003 16 : 173 182.
16. Hicks DG, Tubbs RR. Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines. Hum Pathol 2005 36 : 250 261.
17. Tanner M, Gancberg D, Di Leo A et al. Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol 2000 157 : 1467 1472.
18. Hanna WM, Kwok K. Chromogenic in-situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm. Mod Pathol 2006 19 : 481 487.
19. Burger PC, Pearl DK, Aldape K et al. Small cell architecture - a histological equivalent of EGFR amplification in glioblastoma multiforme? J Neuropathol Exp Neurol 2001 60 : 1099 1104.
20. Quezado M, Ronchetti R, Rapkiewicz A, Santi M, Blumenthal DT, Rushing EJ. Chromogenic in situ hybridization accurately identifies EGFR amplification in small cell glioblastoma multiforme, a common subtype of primary GBM. Clin Neuropathol 2005 24 : 163 169.
21. Kumada T, Tsuneyama K, Hatta H, Ishizawa S, Takano Y. Improved 1-h rapid immunostaining method using intermittent microwave irradiation: practicability based on 5 years application in Toyama Medical and Pharmaceutical University Hospital. Mod Pathol 2004 17 : 1141 1149.
22. Watanabe K, Tachibana O, Sata K, Yonekawa Y, Kleihues P, Ohgaki H. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 1996 6 : 217 223.
23. Kleihues P, Ohgaki H. Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro-oncology 1999 1 : 44 51.
24. Ohgaki H, Dessen P, Jourde B et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res 2004 64 : 6892 6899.
25. Ohgaki H, Schauble B, zur Hausen A, von Ammon K, Kleihues P. Genetic alterations associated with the evolution and progression of astrocytic brain tumours. Virchows Arch 1995 427 : 113 118.
26. Fukushima T, Favereaux A, Huang H et al. Genetic alterations in primary glioblastomas in Japan. J Neuropathol Exp Neurol 2006 65 : 12 18.
27. Tohma Y, Gratas C, Biernat W et al. PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas. J Neuropathol Exp Neurol 1998 57 : 684 689.
28. Tohma Y, Gratas C, Van Meir EG et al. Necrogenesis and Fas/APO-1 (CD95) expression in primary (de novo) and secondary glioblastomas. J Neuropathol Exp Neurol 1998 57 : 239 245.
29. Homma T, Fukushima T, Vaccarella S et al. Correlation among pathology, genotype, and patient outcomes in glioblastoma. J Neuropathol Exp Neurol 2006 65 : 846 854.